Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical study of aclacinomycin A.

M Ogawa, J Inagaki, N Horikoshi

    Cancer Treatment Reports
    |May 1, 1979
    PubMed
    Summary

    A phase I study evaluated aclacinomycin A, an anthracycline antibiotic, in advanced cancer patients. Hepatic and hematologic toxicities were dose-limiting, establishing a recommended dose for further trials.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Unrelated cord blood transplantation in aplastic anemia: is anti-thymocyte globulin indispensable for conditioning?

    Bone marrow transplantation·2017
    Same author

    Association of immunoglobulin G4 and free light chain with idiopathic pleural effusion.

    Clinical and experimental immunology·2017
    Same author

    Heterogeneous response to recombinant thrombomodulin by grade of sinusoidal obstructive syndrome after pediatric stem cell transplantation.

    Bone marrow transplantation·2016
    Same author

    Formation of Flower Fragrance Compounds from Their Precursors by Enzymic Action during Flower Opening.

    Bioscience, biotechnology, and biochemistry·2016
    Same author

    Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma.

    Blood cancer journal·2015
    Same author

    Salvage allogeneic hematopoietic SCT for primary graft failure in children.

    Bone marrow transplantation·2013

    Area of Science:

    • Oncology
    • Pharmacology
    • Clinical Trials

    Background:

    • Anthracycline antibiotics are crucial in cancer chemotherapy.
    • Aclacinomycin A is a novel anthracycline with potential anti-cancer activity.
    • Understanding its toxicity profile and maximum-tolerated dose is essential for clinical application.

    Purpose of the Study:

    • To determine the maximum-tolerated dose (MTD) of aclacinomycin A.
    • To assess the safety and toxicity profile of aclacinomycin A in patients with advanced malignancy.
    • To establish a recommended dose for phase II clinical trials.

    Main Methods:

    • A phase I clinical trial was conducted.
    • Fifteen patients with advanced malignancies were enrolled.
    • Dose escalation was performed to identify the MTD.

    Main Results:

    • Gastrointestinal toxicity was not severe and not dose-related.
    • Epilation and stomatitis were minimal side effects.
    • Hepatic dysfunction and hematologic toxicity were dose-limiting, defining the MTD.
    • A recommended dose of 2.5–3.0 mg/kg (100–120 mg/m2) every 3 weeks was determined.
    • Two patients with malignant lymphomas showed an objective response.

    Conclusions:

    • Aclacinomycin A demonstrates a manageable toxicity profile.
    • Hepatic and hematologic toxicities are the primary dose-limiting factors.
    • The recommended dose for phase II studies is 2.5–3.0 mg/kg every 3 weeks.
    • Aclacinomycin A showed preliminary efficacy in malignant lymphomas.

    Related Experiment Videos